Bio waiver for lower strength (250mg) Mycophenolate mofetil tablet [Regulatives / Guidelines]

posted by Nidhiya J S – United Arab Emirates, 2019-11-05 05:14 (532 d 21:21 ago) – Posting: # 20749
Views: 2,996

(edited by Nidhiya J S on 2019-11-06 05:08)

Dear All,


Please, I would like to know that, with the In vitro comparative dissolution study report can we waive off BE In vivo study with in vitro comparative dissolution study for the lower strength for Mycophenolate mofetil tablet 250mg or do we require separate BE study for the lower strength.

And also I would like to know that whether similar approach can be taken for all the pro-drug where the metabolite of the drug is pharmacologically active.

Waiting for your valuable comments.

With Regards,


Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 8 (0 registered, 8 guests [including 3 identified bots]).
Forum time: Wednesday 02:35 UTC (Europe/Vienna)

In the Middles Ages the lingua franca of science was Latin.
Nowadays the language of science is bad English.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz